Cover Image
市場調查報告書

搭配診斷的全球市場 ∼2022年:PCR、IHC、NGS、ISH

Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User - Global Forecast to 2022

出版商 MarketsandMarkets 商品編碼 538593
出版日期 內容資訊 英文 178 Pages
訂單完成後即時交付
價格
Back to Top
搭配診斷的全球市場 ∼2022年:PCR、IHC、NGS、ISH Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User - Global Forecast to 2022
出版日期: 2017年08月01日 內容資訊: 英文 178 Pages
簡介

全球搭配診斷的市場在預測期間內,預計以20.1%的年複合成長率發展,從2017年的26億1000萬美元,成長到2022年的65億1000萬美元的規模。法律規章上的指南的整備,標靶治療的需求擴大,癌症的罹患率的上升,搭配診斷實驗的開發相關聯盟、合作關係的擴大等要素,促進該市場的成長。

本報告提供全球搭配診斷的市場調查,市場定義和概要,市場成長的各種影響因素及市場機會分析,各產品&服務、技術、適應症、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場概要
  • 各適應症市場
  • 各產品與服務市場
  • 各技術市場

第5章 市場概要

  • 簡介
  • 市場動態
    • 成長推動因素
    • 阻礙成長要素
    • 市場機會
    • 課題

第6章 市場分析:各產品與服務

  • 簡介
  • 化驗套件、試劑
  • 軟體、服務

第7章 市場分析:各技術

  • 簡介
  • 聚合酵素鏈鎖反應 (PCR)
  • 免疫組織化學
  • 原位雜合反應
  • 次世代定序
  • 其他

第8章 市場分析:各適應症

  • 簡介
  • 癌症
    • 乳癌
    • 肺癌
    • 大腸癌
    • 黑色素瘤
    • 胃癌
    • 其他
  • 神經科
  • 感染疾病
  • 其他

第9章 市場分析:各終端用戶

  • 簡介
  • 醫藥品、生物醫藥品企業
  • 參考實驗室
  • 其他

第10章 地區分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 亞太地區
  • 其他地區

第11章 競爭環境

  • 簡介
  • 市場排行榜
  • 競爭領導製圖
  • 競爭基準
    • 產品系列
    • 產業策略

第12章 企業簡介

  • F. HOFFMANN-LA ROCHE AG
  • AGILENT TECHNOLOGIES, INC.
  • QIAGEN N.V.
  • THERMO FISHER SCIENTIFIC INC.
  • ABBOTT LABORATORIES, INC.
  • BIOMERIEUX SA
  • DANAHER CORPORATION
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • ARUP LABORATORIES INC.
  • SYSMEX CORPORATION
  • HOLOGIC INC.
  • NOVARTIS AG
  • ALMAC GROUP
  • ABNOVA CORPORATION

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 5463

"Global companion diagnostics market projected to grow at CAGR of 20.1%"

The global companion diagnostics market is projected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. However, uncertain reimbursement scenarios in different countries such as the U.S., the U.K., Japan, and Australia are expected to limit market growth.

"The assay kits & reagents segment is expected to grow at the fastest CAGR"

On the basis of product and service, the companion diagnostics market is segmented into assay kits & reagents, and software & services. The assay kits & reagents segment accounted for the largest share in 2016 and is expected to register the highest CAGR during the forecast period. The large share can be attributed to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH.

"The oncology segment to dominate the global companion diagnostics market with largest share and fastest CAGR"

Based on indication, the companion diagnostics market is further categorized into oncology, infectious diseases, neurology, and other indications (including cardiovascular, inflammatory, and inherited diseases). In 2016, the oncology segment accounted for the largest share and is also the fastest growing segment of the market; this is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also broadened the role of companion diagnostics in this field.

"The pharmaceutical and biopharmaceutical companies segment is expected to grow at the fastest CAGR"

On the basis of end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2016. This end-user segment is also expected to register the highest CAGR during the forecast period. The large share and growth of this market can be attributed to increasing and significant application of companion diagnostics in the drug development process.

"Asia-Pacific to witness the fastest growth during the forecast period (2017-2022)"

North America held the largest share of the global companion diagnostics market in 2016, while Asia-Pacific is expected to witness the highest growth during 2017 to 2022. Growing need for tailored therapeutics by the elderly population, increasing number of hospitals and diagnostic laboratories, and growing prevalence of life-threatening diseases are driving the growth of the companion diagnostics market in the Asia-Pacific region.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-45%, Tier 2-34%, and Tier 3-21%
  • By Designation - C-level-14%, Director Level-10%, and Others-76%
  • By Region - North America-40%, Europe-32%, Asia-Pacific-20%, and RoW-8%

Some of the major market players in the companion diagnostics market are: F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), and QIAGEN N.V. (Netherlands) dominated the global companion diagnostics market. Some of the other players competing in this market are Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Danaher Corporation (U.S.), Almac Group (U.S.), and Sysmex Corporation (Japan).

Research Coverage:

The report analyzes the companion diagnostics market and aims at estimating market size and future growth potential of this market based on various segments such as product and service, type of medical device, application, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product and service portfolios offered by the top players in the global companion diagnostics market. The report analyzes the global companion diagnostics market by product and service, technology, indication, end user, and region
  • Product/Service Enhancement/Innovation: Detailed insights on upcoming trends and new product/service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging markets by product and service, type of medical device, application, and region
  • Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, services, and capabilities of leading players in the global market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED IN THE REPORT
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
      • 2.2.2.1. Key industry insights
    • 2.2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL COMPANION DIAGNOSTICS MARKET OVERVIEW
  • 4.2. COMPANION DIAGNOSTICS MARKET, BY INDICATION
  • 4.3. COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
  • 4.4. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Improvements in regulatory guidelines
      • 5.2.1.2. Growing need for targeted therapies
      • 5.2.1.3. Rising cancer incidence worldwide
      • 5.2.1.4. Increasing collaborations and partnerships for companion diagnostics test development
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Uncertain reimbursement scenario in different regions
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing demand for next-generation sequencing(NGS)
      • 5.2.3.2. Increasing number of clinical trials to boost adoption of companion diagnostics
      • 5.2.3.3. Emerging applications of companion diagnostics in other cancer indications, neurological disorders, infectious diseases, and CVDs
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Intellectual property rights protection issues

6. COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1. INTRODUCTION
  • 6.2. ASSAYS AND REAGENTS
  • 6.3. SOFTWARE & SERVICES

7. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. POLYMERASE CHAIN REACTION (PCR)
  • 7.3. IMMUNOHISTOCHEMISTRY (IHC)
  • 7.4. IN SITU HYBRIDIZATION (ISH)
  • 7.5. NEXT-GENERATION SEQUENCING (NGS)
  • 7.6. OTHER TECHNOLOGIES

8. COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 8.1. INTRODUCTION
  • 8.2. ONCOLOGY
    • 8.2.1. BREAST CANCER
    • 8.2.2. LUNG CANCER
    • 8.2.3. COLORECTAL CANCER
    • 8.2.4. MELANOMA
    • 8.2.5. GASTRIC CANCER
    • 8.2.6. OTHER CANCERS
  • 8.3. NEUROLOGY
  • 8.4. INFECTIOUS DISEASES
  • 8.5. OTHER INDICATIONS

9. COMPANION DIAGNOSTICS MARKET, BY END-USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
  • 9.3. REFERENCE LABORATORIES
  • 9.4. OTHER END-USERS

10. COMPANION DIAGNOSTICS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. U.K.
    • 10.3.4. REST OF EUROPE
  • 10.4. ASIA-PACIFIC
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET RANKING ANALYSIS
  • 11.3. COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1. VISIONARY LEADERS
    • 11.3.2. INNOVATORS
    • 11.3.3. DYNAMIC DIFFERENTIATORS
    • 11.3.4. EMERGING COMPANIES
  • 11.4. COMPETITIVE BENCHMARKING
    • 11.4.1. STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS)
    • 11.4.2. BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS)

12. COMPANY PROFILES (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

  • 12.1. F. HOFFMANN-LA ROCHE AG
  • 12.2. AGILENT TECHNOLOGIES, INC.
  • 12.3. QIAGEN N.V.
  • 12.4. THERMO FISHER SCIENTIFIC INC.
  • 12.5. ABBOTT LABORATORIES, INC.
  • 12.6. BIOMERIEUX SA
  • 12.7. DANAHER CORPORATION
  • 12.8. ILLUMINA, INC.
  • 12.9. MYRIAD GENETICS, INC.
  • 12.10. ARUP LABORATORIES INC.
  • 12.11. SYSMEX CORPORATION
  • 12.12. HOLOGIC INC.
  • 12.13. NOVARTIS AG
  • 12.14. ALMAC GROUP
  • 12.15. ABNOVA CORPORATION

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: GLOBAL COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO
  • TABLE 2: PARTNERSHIPS AND COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
  • TABLE 3: LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
  • TABLE 4: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2015-2022 (USD MILLION)
  • TABLE 5: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 6: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 7: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 8: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 9: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 10: EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 12: COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
  • TABLE 13: PCR COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: NORTH AMERICA: PCR COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 15: EUROPE: PCR COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 16: IHC COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17: NORTH AMERICA: IHC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 18: EUROPE: IHC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 19: ISH COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: NORTH AMERICA: ISH COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 21: EUROPE: ISH COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 22: NGS COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: NORTH AMERICA: NGS COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 24: EUROPE: NGS COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 25: OTHER TECHNOLOGIES: COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 26: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 27: EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 28: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 29: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 30: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 31: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 32: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 33: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 34: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 35: EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 36: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 38: EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 39: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 40: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 41: EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 42: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 43: PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES END-USER: COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 44: PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES END-USER: NORTH AMERICA COMPANION DIAGNOSTICS MARKET FOR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 45: PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES END-USER: EUROPE COMPANION DIAGNOSTICS MARKET FOR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 46: REFERENCE LABORATORIES END-USER: COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 47: REFERENCE LABORATORIES END-USER: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 48: REFERENCE LABORATORIES END-USER: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 49: OTHER END-USERS: COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 50: OTHER END-USERS: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 51: OTHER END-USERS: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 52: COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 53: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 54: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 55: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 56: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 57: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 58: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 59: U.S.: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 60: U.S.: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 61: U.S.: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 62: U.S.: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 63: U.S.: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 64: CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 65: CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 66: CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 67: CANADA: COMPANION DIAGNOSTICS MARKET SIZE FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 68: CANADA: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 69: EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 70: EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 71: EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 72: EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 73: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 74: EUROPE: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 75: GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 76: GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 77: GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 78: GERMANY: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 79: GERMANY: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 80: FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 81: FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 82: FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 83: FRANCE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 84: FRANCE: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 85: U.K.: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 86: U.K.: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 87: U.K.: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 88: U.K.: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 89: U.K.: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 90: REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 91: REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 92: REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 93: REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 94: REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 95: ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 96: ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 97: ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 98: ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 99: ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 100: ROW: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 101: ROW: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 102: ROW: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 103: ROW: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 104: ROW: COMPANION DIAGNOSTICS MARKET, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 105: RANKING OF COMPANIES IN COMPANION DIAGNOSTICS MARKET, 2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BOTTOM-UP APPROACH
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2022, (USD BILLION)
  • FIGURE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2022, USD BILLION
  • FIGURE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2022, USD BILLION
  • FIGURE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END-USER, 2017-2022 (USD BILLION)
  • FIGURE 10: GLOBAL COMPANION DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 11: INCREASING DEMAND FOR TARGETED THERAPY BOOSTING MARKET GROWTH
  • FIGURE 12: ONCOLOGY SEGMENT TO HOLD LARGEST MARKET SHARE IN 2017
  • FIGURE 13: ASSAYS & REAGENTS SEGMENT TO HOLD LARGEST MARKET SHARE IN 2017
  • FIGURE 14: PCR SEGMENT TO HOLD LARGEST MARKET SHARE IN 2017
  • FIGURE 15: COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE, 2012 VS. 2015 VS. 2020 (MILLION)
  • FIGURE 17: ASSAYS & REAGENTS TO CONTINUE DOMINATING COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 18: PCR TECHNOLOGY TO CONTINUE DOMINATING COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 19: ONCOLOGY INDICATION TO DOMINATE COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 20: PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES END-USER SEGMENT TO CONTINUE DOMINATING MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 21: GLOBAL COMPANION DIAGNOSTICS MARKET GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 22: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 23: EUROPE: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 24: ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 25: COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 26: F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2016)
  • FIGURE 27: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 28: QIAGEN N.V.: COMPANY SNAPSHOT (2016)
  • FIGURE 29: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 30: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 31: BIOMERIEUX SA: COMPANY SNAPSHOT (2016)
  • FIGURE 32: DANAHER CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 33: ILLUMINA, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 34: MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 35: SYSMEX CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 36: HOLOGIC, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 37: NOVARTIS AG: COMPANY SNAPSHOT (2016)
Back to Top